Trial Profile
A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous MTP-131 on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention and Stenting for ST-segment Elevation Myocardial Infarction Infarction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Elamipretide (Primary)
- Indications Myocardial reperfusion injury
- Focus Therapeutic Use
- Acronyms EMBRACE-STEMI
- Sponsors Stealth BioTherapeutics
- 16 Nov 2016 Results of a subgroup analysis (n=271) presented at the 89th Annual Scientific Sessions of the American Heart Association
- 15 Jun 2016 Results (n=100) of post-host analysis evaluating the association between infarct sixe and LV mass, published in the American Journal of Cardiology
- 19 Nov 2015 Results published in the European Heart Journal